


— Dupilumab — Mepolizumab — Omalizumab



Number at risk 0 30 60 90 120 150 180 210 240 270 300 330 360

Follow-up days

Dupilumab	68	67	67	67	67	67	66	66	65	65	65	64	63
Mepolizumab	65	65	64	64	64	62	60	60	60	59	59	58	58
Omalizumab	68	67	67	67	67	67	66	66	65	65	65	65	65